acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How can anyone with any common sense sell $AMBS shares here?
Lincoln Park Capital is in for $20,000,000 and now Cavendish Global with access to $200B in investment capital has jumped on the bandwagon.
Milestones and catalysts about to come to fruition.
Anyone who doesn't see the opportunity here should get out of the market.
Expecting Chairman's blog soon. Additional updates from Dr. Urano also expected.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. Good chance the share price is at .15 by Friday.
The value of Afrezza will be based on the label that the F.D.A. allows, any additional REMS, and whether or not periodic lung function tests are required.
This is why Mannkind hasn't been able to find a marketing partner for Afrezza.
Would you pay $25,000 for a car if you didn't know the year of the car, the make, the model, or the condition of the car?
It reminds me of Gerald's comment in regards to the value of a LymPro partnership, "Someone may offer you "X" today when in three months they'll offer you 200 times "X"."
It's been more than three months and I'm expecting more than 200 times.
Overdue for news especially a Chairman's blog.
Twitter: @AmarantusBio .... 10,000 followers.
"Technology Helps Recruit and Enroll the Right Patients for Clinical Trials"
"This makes the effort of recruiting qualified patients, and retaining those enrolled patients through the end of a study, the greatest barriers to clinical trial completion and time to a full data set for analysis and evaluation. Nearly eighty percent of clinical trials in the U.S. do not meet enrollment timelines and dropout rates are significant."
http://patientpoint.com/blog/technology-helps-recruit-and-enroll-the-right-patients-for-clinical-trials
"Big pharma" will demand access to LymPro.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
It's quite possible that if the F.D.A. decides not to approve Mannkind's Afrezza on July 15 or approves it with a bad label, with significant REMS requirements, and also requires periodic lung function testing for all users that Amarantus could possibly acquire Mannkind in a year or two.
If Mannkind doesn't find a marketing partner for Afrezza and has to market Afrezza "in-house" I think as Adam Feuerstein stated, "the commercial launch of Afrezza will be a disaster".
Although Mannkind hasn't found anyone interested in its Technosphere drug delivery system even though they've had it for more than a decade it still may be of some interest to Amarantus as the company always seems ready to acquire new products.
I think Gerald is on the same page if the anticipated milestones come to fruition.
Next six weeks should add clarity as to what to expect in regards to the company's uplisting strategy.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. I seriously doubt that the share price will ever go below .10 again. I expect Monday's closing price will substantially support this belief.
Time to start accumulating. Buy the dips.
There is no way of knowing what the "true short interest" actually is.
Great post.
p.s. How does someone contact IHub admin to file a complaint?
Most individuals don't realize how heavy the short volume has been in trying to keep the share price in check.
Over the last eleven trading sessions the short volume has been 47.65% of the total volume.
http://otcshortreport.com/index.php?index=ambs&action=view#.U5yzuSgkRqM
This is setting up for a major short squeeze.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
Why $AMBS's Share Price Is Going Much Higher
$AMBS's share price will continue to climb. Lincoln Park Capital (LPC) is committed to investing $20M with the tranches occurring at the time Gerald decides to sell the shares. The shares will be sold at no discount to the market. Considering the company's current cash on hand the first sale to LPC will occur when the share price is in the the .25-.30 range or higher. A number of expected milestones such as the news of a LymPro partnership which is expected at any time will take it there.
LPC knows that when it is announced that it has invested another $4-$5 million in $AMBS that the news will spike the share price especially as it will happen as milestones are achieved. Knowing that it will be purchasing shares at .25 it's obviously in LPC's best interest to purchase millions of cheap shares at the current low price and as it climbs towards the .25 range. It's one of the smartest investments that LPC can make currently. It's similar to you placing a bet on something for which you already know the outcome. When LPC made the decision to invest $20,000,000 in the company I can only imagine the due diligence that occurred to allow LPC to make the decision knowing they would be purchasing shares at no discount to the market. Obviously they had access to information that we don't have as retail investors.
Cavendish Global becoming a supporter with their associates having over $200B in investment capital will also contribute to the share price continued move higher.
The milestones and catalysts that will occur over the next weeks, months, and years make $AMBS the best investment opportunity in the market.
99% of the individuals that will own shares in $AMBS two years from now still haven't heard of the company or it's products. LymPro and MANF are about to change that.
Don't miss "buying" at the bottom. It isn't going lower.
"The next Amgen in it's infancy."
Twitter: @AmarantusBio .... 10,000 followers
I'm somewhat certain that Gerald and Dr. Urano will be meeting this weekend.
The up trend is just beginning.
.25 on July 15 is probably on the low side of where the share price will be.
47.1% "short" shares today. It's only a matter of time before the shorts get torched.
http://otcshortreport.com/index.php?index=AMBS&action=view#.U5twtyj43Ng
Stay tuned for news.
If anyone wants to sell now someone will buy your shares.
The stock is under heavy accumulation.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. Gerald, how about a Chairman's blog to update the shareholders and the market on the milestones.
Is there a development partnership in the works for MANF for diabetes?
Is that why Gerald can't comment on MANF as it relates to diabetes?
Specific Protein May Help Beta Cells Survive in Type 1 Diabetes
http://jdrf.org/blog/2014/specific-protein-may-help-beta-cells-survive-in-type-1-diabetes-2/
American Diabetes Association Conference starts today:
http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=93229
Overdue for a Chairman's blog.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
.25-.30 on July 15.
Milestones are about to be hit.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 follower.
p.s. Last Chairman's blog was on March 31. I think the next one will be "monumental" for the shareholders.
Specific Protein May Help Beta Cells Survive in Type 1 Diabetes
http://jdrf.org/blog/2014/specific-protein-may-help-beta-cells-survive-in-type-1-diabetes-2/
American Diabetes Association Conference starts tomorrow:
http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=93229
Overdue for a Chairman's blog.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
No it's not. You just don't get it.
$20,000,000 from Lincoln Park Capital and Cavendish Global's support.
Milestones will happen in their own time.
Media attention for LymPro will be huge.
MANF for diabetes is a gold mine of value.
"Patience is a virtue."
Twitter: @AmarantusBio .... 10,000 followers.
If they weren't smart enough to re-buy those shares they'll be very sorry.
.25 by July 15 seems reasonable.
Overdue for a Chairman's blog.
LPC and Cavendish Global associates are accumulating cheap shares.
LymPro partnership news out at any time.
Twitter: @AmarantusBio .... 10,000 followers.
If LymPro generates the type of media attention that has been given to several of the other diagnostic blood tests for Alzheimer's that are years behind LymPro in development I think the momentum could carry the share price much higher.
Gerald has the right credentials to make Amarantus and LymPro the "darling" of the media crowd.
Interesting weeks ahead.
I'm still amazed that anyone is selling here with so much obvious upside to the share price going forward.
With LPC accumulating shares and the Cavendish Global associates coming on board and the word continuing to get out to the market about the company's tremendous potential I can't imagine anyone holding a short position in $AMBS over night. The potential for upside momentum at any time is much too great.
Stay the course.
Twitter: @AmarantusBio .... 10,000 followers.
Strong accumulation and the up trend continues.
I still think it will take only one p.r. to gap the share price above Napadano's .20 valuation.
I.R. says the company is on-track to meet all the previously indicated milestones. I think they'll be a few milestones of which we are not currently aware. Surprise can be a good thing.
LymPro partnership could be announced at any time.
Cavendish Global's continued involvement with the company "is" a big deal. Give major credibility to Gerald and his management team for getting them on board.
Expecting MANF to be a major topic of discussion at the A.D.A. Conference which starts on Friday. Something is in the works in the field of diabetes. Development partnership?
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. Overdue for a Chairman's blog.
There's an old saying that says someone "can't see the forest for the trees".
http://www.urbandictionary.com/define.php?term=can%27t%20see%20the%20forest%20for%20the%20trees&defid=6727918
It is best to view Amarantus's tremendous potential with so many potential catalysts as the forest.
So much potential for less than a dime a share. It won't be this cheap much longer.
Twitter: @AmarantusBio .... 10,000 followers.
"3 Reasons to Buy Barrick Gold"
http://www.fool.ca/2014/06/10/3-reasons-to-buy-barrick-gold/?source=c75yhocs0040001
5,000% upside in three years isn't out of the question if LymPro, Eltoprazine, and MANF are what I expect them to be.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. If you disagree that is your choice.
Sometimes on a clear night four or five aircraft can be seen lined up into the distance for landing at LAX.
I think this is a good analogy to the milestones and catalysts that will be announced by the company over the next six months.
Don't be short or on the sidelines as they are announced.
L.P.C. had to know what to expect before they committed the $20,000,000 to $AMBS.
Stay tuned for the "arrival" news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. Time for a Chairman's blog.
Do you think L.P.C. invests $20,000,000 in $AMBS at no discount to the market and with the company dictating the time of the purchases unless L.P.C. knows of major catalysts that will impact the share price?
I remember Gerald's comment to me regarding the need for a reverse split prior to the up-listing:
"If we hit a couple of our milestones a reverse split may not be necessary."
Gift at the current price.
Expecting a new Chairman's blog at any time.
Twitter: @AmarantusBio .... 10,000 followers.
All signs are pointing to buying "NUGT" here.
The shorts and the penny flippers are backing off on the selling. The shorts don't want to get burned and the flippers don't want to get left behind.
Torched shorts and forgotten flippers on the next news.
Interesting days, weeks, months, and years ahead.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. Chairman's blog is overdue.
"Record Gold/Silver Futures Shorting Bullish Omen For Precious Metals"
http://seekingalpha.com/article/2257163-record-gold-silver-futures-shorting-bullish-omen-for-precious-metals
Time to buy "NUGT".
"Record Gold/Silver Futures Shorting Bullish Omen For Precious Metals"
http://seekingalpha.com/article/2257163-record-gold-silver-futures-shorting-bullish-omen-for-precious-metals
Time to buy "NUGT".
I hope the shorts are able to short millions of share under a dime. Millions under nine cents would be even better.
When the news hits and the shorts have to compete with new buyers and other shorts struggling to cover that is when you'll see what a real short squeeze can do to the share price.
Not if but when.
Stay tuned for news.
Twiiter: @AmarantusBio .... 10,000 followers.
p.s. Best short squeeze ever was VRML. Check its five year chart. .01 to $33.55.
Many of the bashers/naysayers tend to forget the "fact" that the company dictates when L.P.C. must purchase $AMBS shares and there is no discount to the market.
L.P.C. obviously has better information than anyone posting here and they chose to "pony up" the $20M.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. How many individuals on the board would commit to purchasing $10K,$25K, or $50K of $AMBS shares from the company and allow the company to dictate when those purchases were to occur and with no discount to the market?
Stealing shares without a gun.
Enjoy the ride.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. The shorts won't know what hit them.
Great chart.
It still doesn't reflect that one p.r. that will double or triple the share price in a day.
What will be the catalyst?
LymPro partnership.
Development partnership for MANF for one of its "orphan indications".
N.I.H. grant news.
MJFF grant news.
N.F.L./G.E. grant news.
Development partnership for Eltoprazine.
Interesting times ahead for the shareholders.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. Last Chairman's blog was posted on March 31. Time for an update.
Gerald has stated that there are certain things on which he can't comment because of an N.D.A. being in place. He has also declined to answer questions regarding MANF in the field of diabetes by saying that he can't comment about it. The logical conclusion is that one of the N.D.A. in place is related to MANF in the field of diabetes. It would be great if the N.D.A. is related to a development partnership with a "big pharma" company such as Novartis which would generate a substantial up-front cash payment and milestone payments over the next three or four years.
In light of the research that Dr. Urano is pursuing as it relates to MANF it's likely that more attention will be drawn to the company by "big pharma" and potential new shareholders.
It's also good timing that the A.D.A. meeting is in AMBS's backyard:
American Diabetes Association
74th Scientific Sessions
June 13 - 17, 2014, San Francisco, California
http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=93229
It's only a matter of time before that one p.r. doubles or triples the share price in a day.
Ask yourself a simple question: Is it better to buy that "Caramel Frappuccino" at Starbucks or 50 shares of $AMBS?
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
p.s. Overdue for a Chairman's blog.
Essentially your post can be summed up in three of the words you posted, "I don't know".
Of course this applies to most of the speculative posts on stock boards including my own.
Partnership news could come at any time.
"Patience is a virtue."
Twitter: @AmarantusBio .... 10,000 followers.
Looking forward to the development partnership announcement for MANF for diabetes.
It certainly will help move the share price higher.
Time to go chase the little white ball - 12:00 tee time.
Have a great day!!!
p.s. Trying to get back home in time to watch the Kings defeat the Rangers.
You are 100% correct.
American Diabetes Association
74th Scientific Sessions
June 13 - 17, 2014, San Francisco, California
http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=93229
I'm expecting multiple partnerships will be announced over the next year. The first one could be announced at any time.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.
Dr. Urano continues to release clues as to where MANF for diabetes is headed. Gerald's inability to comment on MANF as it relates to diabetes is another clue. The announcement of a development partnership for MANF for diabetes could happen at any time.
I'm expecting a new Chairman's blog this coming week with an outline of milestones for 2H2014 culminating in the up-listing to the NASDAQ. The last Chairman's blog was on March 31 so the shareholders deserve an should expect an update from Gerald.
Anyone who thought the share price was going lower than yesterday's low is going to be mistaken. If you can still get in under a dime on Monday I suggest you do so. The clock is ticking.
Interesting weeks, months, and years ahead for the $AMBS shareholders.
"Patience is a virtue."
Twitter: @AmarantusBio .... 10,000 followers.
I wouldn't bet on it.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,000 followers.